How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

576 results for

Antithyroid Antibody

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Determination of Baseline Thyroid Status Values in French Adult Population

healthy volunteers group all healthy volunteers have a blood test performed in the same way. Other: Dosages of Thyroid parameters Dosages of the following parameters: TSH, FT4 FT3, TGAb (Tyroglobulin antibody) , TPO Ab (ThyroPeroxydase Antibody) Outcome Measures Go to Primary Outcome Measures : Determination of the usual values of TSH [ Time Frame: baseline ] Determination of the usual values of TSH after assays on DxI automaton of the Beckman Company according to the standardization 3rd international (...) Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Donors (18-70 years old) volunteers at EFS Exclusion Criteria: pregnancy, known antecedents of thyroid diseases (goiter, nodule, hypo or hyperthyroidism), current antithyroid treatment (neomercazole [Thyrozol(r)], levothyroxyn LT4 [levothyrox(r)], ...), cardiac treatment with amiodarone (cordarone(r)), injection of iodinated contrast medium less than 1 month old Contacts and Locations Go to No Contacts or Locations Provided More Information

2018 Clinical Trials

102. Incidence of neonatal hyperthyroidism among newborns of Graves' disease patients treated with radioiodine therapy. (Abstract)

Incidence of neonatal hyperthyroidism among newborns of Graves' disease patients treated with radioiodine therapy. The serum thyrotropin receptor antibody (TRAb) titers of Graves' disease (GD) patients are known to increase after radioiodine (RAI) therapy, and they can remain high for years. The incidence of neonatal hyperthyroidism (NH) among newborns of mothers with GD who conceived after RAI therapy has not been previously reported. The aims of this study were to investigate the incidence (...) of NH among newborns of mothers who conceived within two years after RAI therapy, and to identify predictors of NH.GD patients (n = 145) who conceived within two years after RAI therapy were retrospectively reviewed, and information regarding their newborns was collected.Of the 145 pregnant women, 54 (37%) were treated with antithyroid drugs or potassium iodide for maternal hyperthyroidism during the first trimester. There were eight newborns with NH, resulting in an incidence of 5.5%. Seven

2018 Thyroid

103. A new highly thyrotropin receptor-selective small molecule antagonist with potential for the treatment of Graves' orbitopathy. (Abstract)

A new highly thyrotropin receptor-selective small molecule antagonist with potential for the treatment of Graves' orbitopathy. The thyrotropin receptor (TSHR) is the target for autoimmune thyroid stimulating antibodies (TSAb) triggering hyperthyroidism. Whereas elevated thyroid hormone synthesis by the thyroid in Graves' disease can be treated by antithyroid agents, for the pathogenic activation of TSHR in retro-orbital fibroblasts of the eye, leading to Graves' orbitopathy (GO), no causal TSHR

2018 Thyroid

104. TPO-Ab plays a role in arterial remodeling in patients with intracranial stenosis. Full Text available with Trip Pro

TPO-Ab plays a role in arterial remodeling in patients with intracranial stenosis. Intracranial stenosis (ICS), the common cause of ischemic stroke worldwide, is associated with a high risk of recurrent stroke. We aimed to investigate the relationship between arterial remodeling and antithyroid peroxidase-antibody (TPO-Ab) level in ICS and the effect of TPO-Ab level on the migration of vascular smooth muscle cells (VSMCs).We analyzed data of mild-to-severe ICS patients with normal thyroid

2018 Atherosclerosis

105. Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features. Full Text available with Trip Pro

a course, 16 are in remission, 1 developed spontaneous hypothyroidism, and 30 (64%) required definitive or long-term treatment (RAI, n = 17; thyroidectomy, n = 5; and long-term ATDs, n = 8). Three cases of thyroiditis and 16 cases of hypothyroidism were documented: 5 with antithyroid peroxidase antibody positivity only, 10 with positive TSH receptor antibody (TRAb), and 1 of uncertain etiology. Bioassay confirmed both stimulating and blocking TRAb in a subset of fluctuating GD cases.Contrary (...) female and 22 male) of patients developed TD, principally GD (71.6%). Median onset was 17 months (range 2 to 107) following the last dose, with the majority (89%) within 3 years. Follow-up data (range 6 to 251 months) were available in 71 case subjects, of whom 52 (73.2%) developed GD: 10 of these (19.2%) had fluctuating TD. All 52 patients with GD commenced antithyroid drugs (ATDs): 3 required radioiodine (RAI) due to ATD side effects, and drug therapy is ongoing in 2; of those who completed

2018 Journal of Clinical Endocrinology and Metabolism

106. The Oral Microbiota is Associated With Autoimmune Thyroiditis

thyroid function changed [ Time Frame: Baseline, 3 months, 6 months, 9 months, 12 months ] Serum thyroid function measured by Immunohistochemistry Other Outcome Measures: Serum thyroid related antibodies changed [ Time Frame: Baseline, 3 months, 6 months, 9 months, 12 months ] Serum thyroid related antibodies measured by Immunohistochemistry Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your (...) Action Antithyroid Agents Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs

2018 Clinical Trials

107. Intestinal Microbiota and Treatment of GD

Secondary Outcome Measures : Serum thyroid function changed [ Time Frame: Baseline, 3 months, 6 months, 9 months, 12 months, 18 months and 24 month respectively after Methimazole withdrawal ] Serum thyroid function measured by Immunohistochemistry Other Outcome Measures: Serum thyroid related antibodies changed [ Time Frame: Baseline, 3 months, 6 months, 9 months, 12 months, 18 months and 24 month respectively after Methimazole withdrawal ] Serum thyroid related antibodies measured (...) Molecular Mechanisms of Pharmacological Action Antithyroid Agents Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs

2018 Clinical Trials

108. A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis

: Screening period (35 days) to complete eligibility assessments Open-label treatment period (6 months) Follow-up period (3 months) During the open-label treatment period, subjects will be randomized to receive romosozumab either via HCP administration with PFS or via self-administration withAI/Pen. During the follow-up period, subjects will be followed for an additional 3 months to ensure appropriate follow-up for anti-romosozumab antibody formation and adverse events. The primary analysis (...) events Incidence of subjects developing anti-romosozumab antibodies [ Time Frame: Month 6 ] Incidence of subjects developing anti-romosozumab antibodies Serum Chemistry [ Time Frame: Month 6 ] Change from baseline in serum chemistry Percent changes from baseline in BMD at femoral neck. [ Time Frame: Month 6 ] Percent changes from baseline in BMD at femoral neck. Incidence of treatment-emergent serious adverse events [ Time Frame: Month 6 ] Incidence of treatment-emergent serious adverse events

2018 Clinical Trials

109. Hashimoto Encephalopathy Full Text available with Trip Pro

Hashimoto Encephalopathy Hashimoto encephalopathy (HE) is a steroid-responsive, acute or subacute encephalopathy, characterised by autoimmune thyroiditis associated with elevated antithyroid antibody titres. An 11-year-old girl was admitted to the Department of Paediatrics with generalised tonic-clonic seizures, left facial paralysis and right hemiparesis. Ceftriaxone and acyclovir were applied, and methyl prednisolone 2 mg kg-1 day-1 was administered orally. The hemiparesis improved on the 3rd (...) day of treatment, but the facial paralysis persisted into the 15th day. When she developed somnolence, she was transferred to the paediatric intensive care unit and provided with respiratory support after intubation. Antithyroid peroxidase (Anti-TPO) and Antithyroglobulin antibody (Anti-Tg) levels were measured at 112.3 IU mL-1 and 74.6 IU mL-1, respectively. HE was considered as the provisional diagnosis, for which intravenous methyl prednisolone 30 mg kg-1 for 5 days followed by prednisolone 1.5

2018 Turkish journal of anaesthesiology and reanimation

110. Evaluation and treatment of recurrent pregnancy loss: a committee opinion

, anti-factor XII, anti- prothrombin, IgA aPLs ANA, antithyroid antibodies Anatomic 1.8–37.6 (mean, 12.6) Hysterosalpingography Sonohysterography Congenital uterine abnormalities Uterine?broids, polyps Cervical incompetence Hormonal or metabolic Prolactin TSH Hemoglobin A1c Uncontrolled diabetes or thyroid disease, prolactin Polycystic ovary syndrome and insulin resistance, luteal phase progesterone Infectious None Bacterial vaginosis, endocervical infections Male factors None Abnormal sperm DNA (...) .2012.06.048 VOL.- NO.- /- 2012 1 PRACTICE COMMITTEETABLE 1 Suspected causes of recurrent pregnancy loss. Cause Contribution to RPL (%) Recommended screening Supportive scienti?c evidence Controversial scienti?c evidence Not recommended Cytogenetic 2–5 Balanced reciprocal translocations aPL syndrome 8–42 (mean, 15) Lupus anticoagulant, anticardiolipin IgG or IgM antibody, anti-b 2- glycoprotein I IgG and IgM antibodies, aPL testing for other phospholipids andb 2 glycoprotein I IgG or IgM anti-annexin A5

2012 Society for Assisted Reproductive Technology

111. Clinical Practice Guidelines for Hypothyroidism in Adults

´-Triiodothyroacetic acid 1010 Thyroid-enhancing preparations 1010 Thyromimetic preparations 1010 Selenium 1010 Questions and Guideline Recommendations 1011 Q1 When should antithyroid antibodies be measured? 1011 R1 TPOAb measurements and subclinical hypothyroidism 1011 R2 TPOAb measurements and nodular thyroid disease 1011 R3 TPOAb measurements and recurrent miscarriage 1011 R4 TSHRAb measurements in women with Graves’ disease who have had thyroidectomy or RAI treatment before pregnancy 1011 Q2 What is the role (...) = thyroxine; TPOAb = anti-thyroid peroxidase antibodies; TRIAC = 3,5,3´-triiodothyroacetic acid; TSH = thyrotropin; TSHRAb, TSH receptor antibodies. Table 1 (Continued)994 For example in some grading systems “should not” implies that there is substantial evidence to support a recommenda- tion. However the grading method employed in this guide- line enables authors to use this language even when the best evidence level available is “expert opinion.” Although different grading systems were employed

2012 American Association of Clinical Endocrinologists

112. Evaluating and managing patients with thyrotoxicosis

uptake and not discriminatory Uptake occasionally seen in type 1 thyroiditis TSH receptor Ab may be present in type 1 thyroiditis if there is underlying Graves disease Type 1 – antithyroid drugs Type 2 – corticosteroids Thyroidectomy may be required Can be difficult to distinguish between type 1 and 2 thyroiditis ESR = erythrocyte sedimentation rate; RAI = radioactive iodine therapy; TA = toxic adenoma; TMNG = toxic multinodular goitre; TPO Ab = thyroid peroxidase antibody; Tg = thyroglobulin; TSH (...) = thyroid peroxidase antibody; Tg = thyroglobulin; TSH receptor Ab = thyroid stimulating hormone-receptor antibody; WBC = white blood count. * Uptake may be low in iodine induced thyrotoxicosisFOCUS Evaluating and managing patients with thyrotoxicosis 568 Reprinted from AustRAliAn F Amily PhysiciAn Vol. 41, no. 8, August 2012 is recommended that propylthiouracil be used in the first trimester and then changed to carbimazole in the second trimester. 4 Antithyroid drugs can be stopped in about 30

2012 Clinical Practice Guidelines Portal

113. Hypothyroidism investigation and management

if there is a convincing clinical picture for hypothyroidism, despite the absence of tsh elevation, to exclude the (much less common) possibility of central hypothyroidism due to pituitary or hypothalamic pathology (Figure 1). thyroid autoantibodies Reprinted from AustRAliAn F Amily PhysiciAn Vol. 41, no. 8, August 2012 557 testing is recommended in euthyroid patients who have positive antithyroid antibodies, as progression to hypothyroidism is more common in this patient group. 2 A diagnosis of hypothyroidism (...) in itself is not an indication for thyroid imaging. thyroid ultrasonography is only indicated to evaluate suspicious structural thyroid abnormalities (ie. palpable thyroid nodules). While thyroid radionucleotide scanning may be useful in elucidating the aetiology of hyperthyroidism, it has no role in the work-up for hypothyroidism. there is an association between chronic thyroiditis and (antithyroid peroxidase and antithyroglobulin antibodies) are positive in 95% of patients with autoimmune thyroiditis

2012 Clinical Practice Guidelines Portal

114. Pregnancy outcomes in women with thyroid peroxidase antibodies. (Abstract)

Pregnancy outcomes in women with thyroid peroxidase antibodies. To estimate the prevalence of antithyroid peroxidase antibodies in the general obstetric population and to compare pregnancy outcomes in women who are antithyroid peroxidase-antibody positive with those who are antithyroid peroxidase-antibody negative.Between November 2000 and April 2003, all women who presented for prenatal care underwent thyroid screening. Serum samples from women without clinical hypothyroidism who had been (...) screened in the first 20 weeks of gestation and delivered a singleton newborn weighing 500 g or more were analyzed for concentrations of antithyroid peroxidase antibodies. Serum thyroid peroxidase antibody levels were determined using a chemiluminescent immunoassay. Pregnancy outcomes in women with positive antithyroid peroxidase antibodies (more than 50 international units/mL) were compared with those with negative levels.Serum samples from 17,298 women were tested. Of these, 1,012 (6%) women were

2010 Obstetrics and Gynecology

115. Investigations of Thyroid Hormones and Antibodies in Obesity: Leptin Levels Are Associated with Thyroid Autoimmunity Independent of Bioanthropometric, Hormonal, and Weight-Related Determinants. Full Text available with Trip Pro

the susceptibility to develop autoimmune thyroid disease (AITD).This cross-sectional study was performed in a tertiary care center.Free thyroid hormones, TSH, thyroglobulin, and antithyroid antibodies levels were tested in 165 obese and 118 lean subjects. Results were plotted against variables related to body composition, leptin levels, glucose homeostasis, energy expenditure, and pattern of weight accrual.Compared with controls, obese patients had lower free T3 levels and free T4 levels (P<0.01), greater (...) prevalence of hypothyroidism (P<0.05), and higher commonness of antithyroid antibodies (P<0.05). As a marker of AITD, thyroid peroxidase antibodies were more frequent in the obese group (P<0.01). Correlation analysis showed that leptin levels were associated with AITD (P<0.01) independent of bioanthropometric variables. Multiple logistic regression analysis in pooled groups identified female sex and leptin as significant predictors of AITD.Obesity increases the susceptibility to harbor AITD

2010 Journal of Clinical Endocrinology and Metabolism

116. Transient Hypothyroidism and Autoimmune Thyroiditis in Children with Chronic Hepatitis C Treated with Pegylated-Interferon-α-2b and Ribavirin. Full Text available with Trip Pro

and ribavirin (RBV).Sixty-one otherwise healthy children with CHC, 3-17 years of age, infected perinatally and treatment naïve, receiving therapy with pegylated IFN-α-2b and RBV and 183 age- and sex-matched controls were included in a multicenter, prospective, case-control study. Thyroid-stimulating hormone, free thyroxine, antithyroglobulin antibodies and antithyroid peroxidase antibodies were assessed before, during and 24 weeks after the end of treatment.From baseline to the end of treatment, subclinical (...) Transient Hypothyroidism and Autoimmune Thyroiditis in Children with Chronic Hepatitis C Treated with Pegylated-Interferon-α-2b and Ribavirin. Autoimmune thyroid disease and thyroid dysfunction are common in adults receiving interferon (IFN)-based treatment for chronic hepatitis C (CHC). Few data are available in children with CHC. This study is aimed to evaluate the appearance and timing of thyroid dysfunction and antithyroid autoimmunity in children with CHC treated with pegylated IFN-α-2b

2017 Pediatric Infectious Dsease Journal

117. Serum 25-hydroxyvitamin D might be an independent prognostic factor for Graves disease recurrence. Full Text available with Trip Pro

Serum 25-hydroxyvitamin D might be an independent prognostic factor for Graves disease recurrence. Graves disease is the most common cause of thyrotoxicosis. Although medical intervention with antithyroid drugs (ATDs) is commonly the first choice of treatment in Korea, the remission rate associated with this approach is not satisfactory. During ATD therapy, low or undetectable serum levels of thyroid-stimulating hormone (TSH) receptor antibodies (TRAbs) have been reported to affect (...) -stimulating antibody [TSAb], as detected by bioassay, and TSH-binding inhibitory immunoglobulins [TBIIs]) were measured, and a thyroid function test was performed upon ATD discontinuation. Recurrence was evaluated every 3 months, and was defined as an occurrence of overt thyrotoxicosis during the follow-up period.A total of 95 patients (66.4%) experienced recurrence with a median latency period of 182 days (ranging 28-1219 days). The serum 25-hydroxyvitamin D levels at the time of ATD discontinuation were

2017 Medicine

118. Single-Session High-Intensity Focused Ultrasound Treatment for Persistent or Relapsed Graves Disease: Preliminary Experience in a Prospective Study. Full Text available with Trip Pro

of the entire right and left thyroid lobes, with areas near the tracheal-esophageal groove and common carotid artery left unablated. Serum thyroid-stimulating hormone (TSH), free T4 (FT4), antithyroid autoantibodies, and TSH receptor (TSHR) antibody levels were evaluated afterward, and US color Doppler, US volumetry, and eye assessment were performed. The primary outcome was the 12-month relapse rate. Relapse referred to hyperthyroidism (FT4 > 23 pmol/L) afterward. Variables associated with relapse were (...) . No changes in gland volume, antithyroid autoantibody levels, and ophthalmic parameters were found at 12-month follow-up. Baseline TSHR was found to have decreased significantly at 6- and 12-month follow-up (P < .001 for both). TSHR antibody (odds ratio [OR] = 1.414; 95% CI: 1.018, 1.965; P = .039) and gland volume (OR = 0.557; 95% CI: 0.353, 0.880; P = .012) were associated with 12-month relapse, with higher antibody levels conferring a higher likelihood and smaller gland volumes conferring a lower

2017 Radiology

119. DEBATE: IDENTIFYING AND TREATING SUBCLINICAL THYROID DYSFUNCTION IN PREGNANCY: EMERGING CONTROVERSIES. Full Text available with Trip Pro

the treatment of overt hypothyroidism; the management and/or treatment of subclinical hypothyroidism, hypothyroxinemia or antithyroid antibody-positive women should be considered with caution. Important trials have found no clear benefit of treatment of subclinical hypothyroidism in terms of cognitive outcomes; however, other interventional studies appear to reduce some of the obstetric and perinatal complications. As a result, the dilemma between universal screening or selective screening of women at high

2017 European Journal of Endocrinology

120. HIV Reservoir Reduction With Interleukin-2

staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 65 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Written informed consent signed and dated by study participant. Male or female, at least 18 years of age and not older than 65 years of age. HIV-1 infection, documented by and FDA-approved ELISA, EIA, or rapid antibody detection method (...) , and confirmed by a second approved antibody-based test or by a positive approved HIV RNA detection assay. CD4+ T cell count ≥ 350 cells/mm3; HIV-1 RNA < 50 copies/mL obtained within 60 days prior to study entry performed with an FDA-approved HIV-1 RNA assay. Adequate venous access and no other contraindications for leukapheresis Absolute neutrophil count (ANC) > 2000/mm3 Hemoglobin level >10 g/dL (males); > 9.5 g/dL (females) Platelet count >150,000/mm3 Serum creatinine <1.5 mg/dL AST and ALT <2.5 times

2017 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>